Dr. Kees Polderman studied medicine at the University of Amsterdam and trained as an internist and subsequently as an intensivist at the Free University Hospital in Amsterdam. His PhD thesis, entitled “Interactions of endocrine systems with cardiovascular significance”, was completed in 1993. He obtained the European diploma in intensive care medicine in 2000. He has previously worked at the VU University Medical Center in Amsterdam and at the Utrecht University Medical Center in the Netherlands. He moved to the United States in August 2009 to become medical director of Neurocritical care services at the University of Pittsburgh Medical Center.
He is a member of the board of direct ors of the Neurocritical Care Society. He has co-authored 121 international (85 PubMed cited) and 62 national (Dutch) publications. His main lines of research are use of therapeutic hypothermia for neuroprotection and cardioprotection, systemic and cardiovascular consequences of neurological injuries, and quality assessment in the ICU.
Education & Training
|European Diploma in Intensive Care Medicine||2000|
|Dutch board certification in Intensive Care Medicine||1998|
|Board Certification in Internal Medicine||1997|
|ECFMG (US medical license)||1986|
Medical Director of Neurocritical Care Services
Lead investigator (coordinating clinical investigator) for the CAMARO trial. This is a multicentre trial designed to test the feasibility and safety, and then the efficacy, of very early and rapid cooling in patients with acute myocardial infarction and ST elevation (STEMI) requiring emergency coronary intervention.
Member, steering committee of the EUROTHERM study. This is a project initiated and sponsored by the European Society of Intensive Care Medicine. The aim is to test the efficacy of therapeutic hypothermia to control intracranial pressure and improve outcome in patients with severe traumatic brain injury and increased intracranial pressure.